AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Large ribosomal subunit protein eL15

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We use our state-of-the-art dedicated workflow for designing focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P61313

UPID:

RL15_HUMAN

Alternative names:

60S ribosomal protein L15

Alternative UPACC:

P61313; P39030; P41051; Q5U0C0; Q642I1; Q6IPX6; Q8WYP2; Q96C44; Q9H2E5

Background:

Large ribosomal subunit protein eL15, also known as 60S ribosomal protein L15, is a crucial component of the large ribosomal subunit. The ribosome plays a pivotal role in the cellular process of protein synthesis, translating mRNA into polypeptide chains. This protein's function is integral to the assembly and stability of the ribosome, facilitating efficient protein production.

Therapeutic significance:

Diamond-Blackfan anemia 12, a congenital non-regenerative hypoplastic anemia, is linked to mutations affecting Large ribosomal subunit protein eL15. Understanding the role of Large ribosomal subunit protein eL15 could open doors to potential therapeutic strategies for this condition, highlighting its significance in medical research.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.